CS
SRPT icon

Clear Street’s Sarepta Therapeutics SRPT Stock Holding History

Clear Street’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,000
Closed -$4.97M – 1145
2022
Q3 		$4.97M Buy
+45,000
New +$4.54M 0.12% 85

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clear Street's SRPT Position: Q1 2026 in Review

Clear Street reduced its Sarepta Therapeutics (SRPT) stake by 17% in Q1 2026, selling an estimated $1.39M and leaving 361,391 shares worth $7.86M. The position accounts for 0.03% of the portfolio, ranked #104.

Clear Street first reported a position in SRPT in Q4 2025 and has held it in 2 quarters since. The position peaked at $9.32M in Q4 2025. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Clear Street held 361,391 shares of Sarepta Therapeutics worth $7.86M as of Q1 2026.
  • Clear Street sold 71,605 Sarepta Therapeutics shares in Q1 2026, an estimated $1.39M.
  • Sarepta Therapeutics made up 0.03% of Clear Street's portfolio in Q1 2026, its #104 holding.
  • Clear Street first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Clear Street's Sarepta Therapeutics position peaked at $9.32M in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.